Venetoclax
- Generic Name
- Venetoclax
- Brand Names
- Venclexta, Venclyxto
- Drug Type
- Small Molecule
- Chemical Formula
- C45H50ClN7O7S
- CAS Number
- 1257044-40-8
- Unique Ingredient Identifier
- N54AIC43PW
- Background
Venetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 . Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are important regulators of the apoptotic (programmed cell death) process , . Venetoclax is used to treat chronic lymphocytic leukemia (CLL) and certain types of small lymphocytic lymphoma . CLL is the most prevalent leu...
- Indication
本品与阿扎胞苷联合用于治疗因合并症不适合接受强诱导化疗，或者年龄75岁及以上的新诊断的成人急性髓系白血病患者。
- Associated Conditions
- Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Associated Therapies
- -
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
- Conditions
- Interventions
- First Posted Date
- 2024-05-24
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 120
- Registration Number
- NCT06428019
- Locations
- 🇺🇸
Springfield Clinic /ID# 270145, Springfield, Illinois, United States
🇺🇸Oklahoma Cancer Specialists and Research Institute /ID# 267643, Tulsa, Oklahoma, United States
🇫🇷Centre Hospitalier de la Côte Basque /ID# 266847, Bayonne, Pyrenees-Atlantiques, France
Eltanexor and Venetoclax in Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2024-05-06
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Target Recruit Count
- 60
- Registration Number
- NCT06399640
- Locations
- 🇺🇸
Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States
A Phase I Study Investigating the Combination of the Ziftomenib, Venetoclax and Azacitidine in Pediatric Relapsed and Refractory Acute Leukemias
- Conditions
- Interventions
- First Posted Date
- 2024-05-02
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 22
- Registration Number
- NCT06397027
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)
- Conditions
- Interventions
- Drug: DexamethasoneDrug: VincristineDrug: DaunorubicinDrug: Calaspargase pegolDrug: VenetoclaxDrug: BortezomibDrug: DasatinibDrug: Intrathecal triple therapy (methotrexate + hydrocortisone + cytarabine)Drug: CyclophosphamideDrug: CytarabineDrug: MercaptopurineDrug: NelarabineDrug: MethotrexateDrug: Thioguanine
- First Posted Date
- 2024-04-30
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 145
- Registration Number
- NCT06390319
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
The Efficacy and Safety of Third-generation TKIs Combined With Azacitidine and Bcl-2 Inhibitor in Patients With CML-MBP
- Conditions
- Interventions
- First Posted Date
- 2024-04-30
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT06390306
- Locations
- 🇨🇳
Peking university people's hospital, Beijing, Beijing, China
A Study of AK117 in Combination With Azactidine Plus Venetoclax in Patients With Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2024-04-29
- Last Posted Date
- 2024-04-29
- Lead Sponsor
- Akeso
- Target Recruit Count
- 180
- Registration Number
- NCT06387420
- Locations
- 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Elderly/Unfit Ph- B-ALL
- First Posted Date
- 2024-04-26
- Last Posted Date
- 2024-04-26
- Target Recruit Count
- 53
- Registration Number
- NCT06387121
Chidamide, Venetoclax, and Azacitidine for Newly Diagnosed Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2024-04-26
- Last Posted Date
- 2024-04-30
- Target Recruit Count
- 184
- Registration Number
- NCT06386302
- Locations
- 🇨🇳
Blood Hospital, Tianjin, Tianjin, China
A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy
- Conditions
- Interventions
- First Posted Date
- 2024-04-25
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- OncoVerity, Inc.
- Target Recruit Count
- 120
- Registration Number
- NCT06384261
- Locations
- 🇺🇸
The University of Iowa Hospitals & Clinics, Iowa City, Iowa, United States
🇨🇦Tom Baker Cancer Center-Alberta Health Services - University of Calgary, Calgary, Alberta, Canada
🇨🇦Stollery Children's Hospital-Walter C Mackenzie Health Sciences Centre - University of Alberta, Edmonton, Alberta, Canada
Phase I/II Study of DFP-10917 in Combination With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2024-04-24
- Last Posted Date
- 2024-04-24
- Lead Sponsor
- Delta-Fly Pharma, Inc.
- Target Recruit Count
- 39
- Registration Number
- NCT06382168
- Locations
- 🇺🇸
UCI Chao Family Comprehensive Cancer Center, Orange, California, United States
🇺🇸Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina, United States
🇺🇸University of Vermont Cancer Center, Burlington, Vermont, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.